Form D · Biotechnology

Cancer Prevention Pharmaceuticals, Inc.

Tucson, AZ · CIK 0001471002

Offering snapshot reported Jan 29, 2021 · SEC filing

Reported sold
$400K
Offering amount: $3M
Investors reported
6
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 20, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 29, 2021Initial$400,000No comparison6SEC filing
Sep 14, 2017Initial$5,000,000No comparison1SEC filing
Apr 25, 2017Initial$700,000No comparison8SEC filing
Jan 22, 2016Initial$5,000,000No comparison1SEC filing
Jan 14, 2016Initial$835,000No comparison14SEC filing
Oct 31, 2013Amendment$4,272,500$3,917,500vs Nov 19, 20126SEC filing
Nov 19, 2012Initial$355,000No comparison2SEC filing
Mar 24, 2011Initial$550,000No comparison12SEC filing
Sep 1, 2009Initial$1,250,000No comparison5SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-387825

Source: Form D, filed Jan 29, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Daniel Donovan Director
Eugene W Gerner Director, Executive
Eugene Gerner, Ph.D. Director
Jeffrey Jacob Director, Executive
Andrew Levitch Executive
Richard Love Director
Frank Meyskens Director
Christopher Richied Executive
Jon Saxe Director
John Saxe Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1760 East River Road, Suite 250
Tucson, AZ, 85718